MRD
Recent news mentioning MRD
- — 2026 IMS | Updated FUMANBA-1 Analysis of IASO Bio's FUCASO Reveals That In Vivo Durable Persistence of CAR-T cells Is Associated with Sustained MRD Negativity and Delayed Disease Progression
- — Adaptive Biotechnologies Highlights Role of Highly Sensitive MRD Testing in New International Myeloma Society Definition of Cure
- — Biodesix Advances Two Complementary Approaches to Molecular Residual Disease (MRD) Monitoring
- — Adaptive Biotechnologies Announces Update to NCCN Guidelines® for Multiple Myeloma, Strengthening MRD Testing Recommendations and Specifically Referencing clonoSEQ®
- — Hematogenix's MM MRD Assay Underpins FDA Accelerated Approval of Bristol Myers Squibb's ZENBEXUS™, the First Approved CELMoD Therapy for Multiple Myeloma
- — Hematogenix's Proprietary MM MRD Assay Underpins FDA Accelerated Approval of Bristol Myers Squibb's ZENBEXUS™, the First Approved CELMoD Therapy for Multiple Myeloma